Drug Approval | September 03, 2021
Covid-19 vaccine clinical trial for people with autoimmune disease
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
The company has to approach the DCGI for approval to commence the trials
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
Subscribe To Our Newsletter & Stay Updated
